ArticleNPJ biofilms and microbiomes2021
Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in NPJ biofilms and microbiomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Subpopulations and Intermediate Outcome Measures in COPD Study
Who cites it
50 citing papers in PubMed, 66 citations in OpenAlex.
- Luteolin ameliorates cigarette smoke-induced chronic obstructive pulmonary disease by modulating gut and lung microbiota and amino acid metabolism in C57Bl/6 mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Review
- Characteristics of Respiratory Microbiome in COPD-A Literature Review.Advances in respiratory medicine · 2026Review
- Lipid Metabolism and Obesity in Early Life: Drivers of Chronic Lung Disease From Development to Adulthood.Molecular nutrition & food research · 2026Review
- Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary disease.EBioMedicine · 2026Observational
- Why the COPD Microbiome Matters: How Airway Microbes Shape Disease Severity and Treatment Response.International journal of chronic obstructive pulmonary disease · 2026Review
- Epigenomic study of the lower airway reveals COPD-associated methylation patterns and potential microbiota links.BMJ open respiratory research · 2025Article
- Smoking-induced microbial dysbiosis: a key driver of systemic diseases and emerging therapeutic opportunities.Cell death discovery · 2025Review
- Extracellular iron and the lung microbiome in smoking and COPD.ERJ open research · 2025Article
- Respiratory Microbiota Associations with Asthma Across American and Emirati Adults: A Comparative Analysis.Applied microbiology (Basel, Switzerland) · 2025Article
- Associations of serum and bronchoalveolar immunoglobulins with lung microbiota diversity, B-cell memory phenotypes, and COPD morbidity and exacerbations.Respiratory research · 2025Observational
- The impact of environmental factors on respiratory tract microbiome and respiratory system diseases.European journal of medical research · 2025Review
- Lung Microbiota: From Healthy Lungs to Development of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Review
- Investigation of dynamic microbial migration patterns in the respiratory tract.Frontiers in cellular and infection microbiology · 2025Article
- Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study.International journal of chronic obstructive pulmonary disease · 2025Observational
- Insights into human respiratory microbiome under dysbiosis and its analysis tool.Frontiers in microbiomes · 2025Review
- Investigation of pure lung microbiota in patients with lung cancer after eliminating upper airway contamination: a prospective cohort study.Journal of thoracic disease · 2024Article
- Oral infection with periodontal pathogens induced chronic obstructive pulmonary disease-like lung changes in mice.BMC oral health · 2024Article
- Loss of Airway Phylogenetic Diversity Is Associated with Clinical and Pathobiological Markers of Disease Development in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 13 institutions in 1 country.
Kristopher Opron *Division of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Lesa A Begley *Division of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
John R Erb-DownwardDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Christine FreemanDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Siddharth MadapoosiDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Neil E AlexisUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Igor BarjaktarevicUniversity of California at Los Angeles, Los Angeles, CA, USA.
R Graham BarrColumbia University, New York, NY, USA.
Eugene R BleeckerUniversity of Arizona College of Medicine, Tucson, AZ, USA.
Russell P BowlerNational Jewish Health, Denver, CO, USA.
Stephanie A ChristensonUniversity of California at San Francisco, San Francisco, CA, USA.
Alejandro P ComellasUniversity of Iowa, Iowa City, IA, USA.
Christopher B CooperUniversity of California at Los Angeles, Los Angeles, CA, USA.
David J CouperUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-4313-9235
Claire M DoerschukUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mark T DransfieldUniversity of Alabama at Birmingham, Birmingham, AL, USA.
MeiLan K HanDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Nadia N HanselJohn Hopkins University, Baltimore, MD, USA.
Annette T HastieWake Forest School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0001-6607-7797
Eric A HoffmanUniversity of Iowa, Iowa City, IA, USA.
Robert J KanerWeill Cornell Medical College, New York, NY, USA.
Jerry KrishnanUniversity of Illinois, Chicago, IL, USA.
Wanda K O'NealUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Victor E OrtegaWake Forest School of Medicine, Winston-Salem, NC, USA.
Robert PaineUniversity of Utah, Salt Lake City, UT, USA.
Stephen P PetersWake Forest School of Medicine, Winston-Salem, NC, USA.
J Michael WellsUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Prescott G WoodruffUniversity of California at San Francisco, San Francisco, CA, USA.
Fernando J MartinezWeill Cornell Medical College, New York, NY, USA.
Jeffrey L CurtisDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-5191-4847
Gary B HuffnagleDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Yvonne J HuangDivision of Pulmonary/Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA. yvjhuang@med.umich.edu.ORCID 0000-0002-7497-6597
University of Michigan · USUniversity of North Carolina at Chapel Hill · USWake Forest University · USCornell University · USUniversity of Alabama at Birmingham · USUniversity of California, Los Angeles · USUniversity of Iowa · USColumbia University · USJohns Hopkins University · USNational Jewish Health · USUniversity of Arizona · USUniversity of Illinois Chicago · USUniversity of Utah · US
Funding
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5MVector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Amy Leanne Ryan · 1998 to 2026
$30.5MSPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9MSPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2MSputum Microbial Markers of Type 2-Low AsthmaR01AI129958 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUANG, YVONNE JEAN · 2017 to 2021
$3.6MFunctional Analysis of the Pulmonary Microbiome during COPDR01HL121774 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUFFNAGLE, GARY B · 2017 to 2020
$3.1MDefining Pathways in COPD Patient Oriented ResearchK24HL138188 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MeiLan K Han · 2017 to 2026
$1.2MMentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2MIdentifying the Th2 endotype in COPD: clinical and pathologic implicationsK23HL123778 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTENSON, STEPHANIE A · 2015 to 2019
$847kCorticosteroid effects on bacterial behaviors in the respiratory tractR03HL138310 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUANG, YVONNE JEAN · 2017 to 2018
$155kNHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K23 HL123778NHLBI NIH HHS K24 HL137013NHLBI NIH HHS K24 HL138188NHLBI NIH HHS R01 HL121774NHLBI NIH HHS R03 HL138310NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIAID NIH HHS R01 AI129958NIDDK NIH HHS P30 DK054759NIEHS NIH HHS P30 ES005605
Abstract
Chronic obstructive pulmonary disease (COPD) is heterogeneous in development, progression, and phenotypes. Little is known about the lung microbiome, sampled by bronchoscopy, in milder COPD and its relationships to clinical features that reflect disease heterogeneity (lung function, symptom burden, and functional impairment). Using bronchoalveolar lavage fluid collected from 181 never-smokers and ever-smokers with or without COPD (GOLD 0-2) enrolled in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS), we find that lung bacterial composition associates with several clinical features, in particular bronchodilator responsiveness, peak expiratory flow rate, and forced expiratory flow rate between 25 and 75% of FVC (FEF
Indexed as
AdultAgedBacteriaBronchoalveolar Lavage FluidFemaleForced Expiratory VolumeHumansLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRNA, Ribosomal, 16SSequence Analysis, RNASpirometryRNA, Ribosomal, 16S
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT01969344ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.